Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 13409-13419

  Pinkert, Sandra ^a,b   Klingel, Karin ^c   Lindig, Vanessa ^b   Dörner, Andrea ^b   Zeichhardt, Heinz ^b   Spiller, O Brad ^d   Fechner, Henry ^a,b  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR INFECTION; COEVOLUTION; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CYTOTOXICITY; HEART CELL CULTURE; HEART MUSCLE CELL; HOST CELL; HOST RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; INFECTION RESISTANCE; MALE; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; BIOLOGICAL EVOLUTION; CELL SURVIVAL; CELLS, CULTURED; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; HUMANS; MALE; MICE; MICE, INBRED BALB C; MYOCYTES, CARDIAC; RATS; VIRULENCE;

ADENOVIRIDAE; COXSACKIEVIRUS; MURINAE; RATTUS;

EID: 84855846000     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00621-11     Document Type: Article

References (68)

1. Ahmed, R., et al. 1981. Role of the host cell in persistent viral infection: coevolution of L cells and reovoirus [sic] during persistent infection. Cell 25:325-332.
2. Beaulieux, F., et al. 2005. Cumulative mutations in the genome of Echovirus 6 during establishment of a chronic infection in precursors of glial cells. Virus Genes 30:103-112.
3. Bergelson, J. M., et al. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
4. Borzakian, S., et al. 1992. Persistent poliovirus infection: establishment and maintenance involve distinct mechanisms. Virology 186:398-408.
5. Bowles, N. E., et al. 1993. Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy. J. Med. 24:145-160.
6. Chen, W., and R. S. Baric. 1996. Molecular anatomy of mouse hepatitis virus persistence: coevolution of increased host cell resistance and virus virulence. J. Virol. 70:3947-3960.
7. Chen, W., B. Yount, L. Hensley, and R. S. Baric. 1998. Receptor homologue scanning functions in the maintenance of MHV-A59 persistence in vitro. Adv. Exp. Med. Biol. 440:743-750.
8. Chia, J., A. Chia, M. Voeller, T. Lee, and R. Chang. 2010. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J. Clin. Pathol. 63:165-168.
9. Chow, L. H., C. J. Gauntt, and B. M. McManus. 1991. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab. Invest. 64:55-64.
10. Cohen, J. I., B. Rosenblum, S. M. Feinstone, J. Ticehurst, and R. H. Purcell. 1989. Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J. Virol. 63:5364-5370.
11. Converse, J. L., R. M. Kovatch, J. D. Pulliam, S. C. Nagle, Jr., and E. M. Snyder. 1971. Virulence and pathogenesis of yellow fever virus serially passaged in cell culture. Appl. Microbiol. 21:1053-1057.
12. Coyne, C. B., and J. M. Bergelson. 2006. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124:119-131.
13. de la Torre, J. C., et al. 1988. Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. J. Virol. 62:2050-2058.
14. Dermody, T. S., M. L. Nibert, J. D. Wetzel, X. Tong, and B. N. Fields. 1993. Cells and viruses with mutations affecting viral entry are selected during persistent infections of L cells with mammalian reoviruses. J. Virol. 67:2055-2063.
15. Desailloud, R., F. Sane, D. Caloone, and D. Hober. 2009. Persistent infection of a carcinoma thyroid cell line with coxsackievirus B. Thyroid 19:369-374.
16. Fechner, H., et al. 2007. Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther. 14:960-971.
17. Fechner, H., et al. 2008. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J. Mol. Med. 86:987-997.
18. Fechner, H., et al. 2007. Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Ther. 14:211-218.
19. Fechner, H., et al. 2000. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. 7:1954-1968.
20. Frey, T. K., and M. L. Hemphill. 1988. Generation of defective-interfering particles by rubella virus in Vero cells. Virology 164:22-29.
21. Frisk, G. 2001. Mechanisms of chronic enteroviral persistence in tissue. Curr. Opin. Infect. Dis. 14:251-256.
22. Frisk, G., M. A. Lindberg, and H. Diderholm. 1999. Persistence of coxsackievirus B4 infection in rhabdomyosarcoma cells for 30 months. Arch. Virol. 144:2239-2245.
23. Gibson, J. P., and V. F. Righthand. 1985. Persistence of echovirus 6 in cloned human cells. J. Virol. 54:219-223.
24. Gosselin, A. S., et al. 2003. Poliovirus-induced apoptosis is reduced in cells expressing a mutant CD155 selected during persistent poliovirus infection in neuroblastoma cells. J. Virol. 77:790-798.
25. Grebennikova, T. V., et al. 2004. Genomic characterization of virulent, attenuated, and revertant passages of a North American porcine reproductive and respiratory syndrome virus strain. Virology 321:383-390.
26. Harms, W., et al. 2001. Characterization of human myocardial fibroblasts immortalized by HPV16 E6-E7 genes. Exp. Cell Res. 268:252-261.
27. Heim, A., et al. 1995. Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication. J. Mol. Cell. Cardiol. 27:2199-2208.
28. Heim, A., et al. 1992. Synergistic interaction of interferon-beta and interferon- gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 166:958-965.
29. Holland, J., et al. 1982. Rapid evolution of RNA genomes. Science 215: 1577-1585.
30. Huber, S. A. 1997. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab Invest. 76:691-701.
31. Kandolf, R., et al. 1991. Molecular studies on enteroviral heart disease: patterns of acute and persistent infections. Eur. Heart J. 12(Suppl. D): 49-55.
32. Kimura, E., et al. 2001. Efficient repetitive gene delivery to skeletal muscle using recombinant adenovirus vector containing the coxsackievirus and adenovirus receptor cDNA. Gene Ther. 8:20-27.
33. Klingel, K., et al. 1992. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. U. S. A. 89:314-318.
34. Klingel, K., and R. Kandolf. 1993. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand. J. Infect. Dis. Suppl. 88:79-85.
35. Klingel, K., et al. 1998. Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects. Lab Invest. 78:1227-1237.
36. Lin, F., et al. 2001. Tissue distribution of products of the mouse decayaccelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 104:215-225.
37. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25:402-408.
38. Mahy, B. W. J., A. C. Minson, and G. K. Darby. 1982. Virus persistence, p. 1-13. 33rd symposium of the society for general microbiology. Cambridge University Press, Cambridge, United Kingdom.
39. Mahy, B. W. 1985. Strategies of virus persistence. Br. Med. Bull. 41:50-55.
40. Matteucci, D., et al. 1985. Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J. Virol. 56:651-654.
41. McManus, B. M., et al. 1993. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin. Immunol. Immunopathol. 68:159-169.
42. Melnick, J. L. 1996. Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p. 655-712. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, PA.
43. Mrukowicz, J. Z., et al. 1998. Viruses and cells with mutations affecting viral entry are selected during persistent rotavirus infections of MA104 cells. J. Virol. 72:3088-3097.
44. Nalbantoglu, J., G. Pari, G. Karpati, and P. C. Holland. 1999. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 10:1009-1019.
45. Nomoto, A., N. Iizuka, M. Kohara, and M. Arita. 1988. Strategy for construction of live picornavirus vaccines. Vaccine 6:134-137.
46. Oldstone, M. B. 1989. Viral persistence. Cell 56:517-520.
47. Palacios, G., and M. S. Oberste. 2005. Enteroviruses as agents of emerging infectious diseases. J. Neurovirol. 11:424-433.
48. Pauschinger, M., et al. 2004. Viral heart disease: molecular diagnosis, clinical prognosis, and treatment strategies. Med. Microbiol. Immunol. 193:65-69.
49. Pauschinger, M., et al. 1999. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99:889-895.
50. Pavio, N., et al. 2000. Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus. Virology 274:331-342.
51. Pelletier, I., G. Duncan, N. Pavio, and F. Colbere-Garapin. 1998. Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase. Cell. Mol. Life Sci. 54:1385-1402.
52. Pinkert, S., et al. 2009. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirusadenovirus receptor. Circulation 120:2358-2366.
53. Poidinger, M., R. J. Coelen, and J. S. Mackenzie. 1991. Persistent infection of Vero cells by the flavivirus Murray Valley encephalitis virus. J. Gen. Virol. 72(Pt. 3):573-578.
54. Ron, D., and J. Tal. 1985. Coevolution of cells and virus as a mechanism for the persistence of lymphotropic minute virus of mice in L-cells. J. Virol. 55:424-430.
55. Sawicki, S. G., J. H. Lu, and K. V. Holmes. 1995. Persistent infection of cultured cells with mouse hepatitis virus (MHV) results from the epigenetic expression of the MHV receptor. J. Virol. 69:5535-5543.
56. Schmidtke, M., et al. 2007. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice. J. Med. Virol. 79:1334-1342.
57. Schmidtke, M., et al. 2000. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1. Virology 275:77-88.
58. Selinka, H. C., et al. 2002. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis. J. Med. Virol. 67:224-233.
59. Sevilla, N., and E. Domingo. 1996. Evolution of a persistent aphthovirus in cytolytic infections: partial reversion of phenotypic traits accompanied by genetic diversification. J. Virol. 70:6617-6624.
60. Shi, Y., et al. 2009. Cardiac deletion of the coxsackievirus-adenovirus receptor abolishes coxsackievirus B3 infection and prevents myocarditis in vivo. J. Am. Coll. Cardiol. 53:1219-1226.
61. Spiller, O. B., I. G. Goodfellow, D. J. Evans, J. W. Almond, and B. P. Morgan. 2000. Echoviruses and coxsackie B viruses that use human decayaccelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF. J. Infect. Dis. 181:340-343.
62. Tami, C., et al. 2003. Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J. Virol. 77:1219-1226.
63. Vlaycheva, L. A., and T. J. Chambers. 2002. Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J. Virol. 76:6172-6184.
64. Werk, D., et al. 2009. Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Res. 83:298-306.
65. Werk, D., et al. 2005. Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor. Biol. Chem. 386:857-863.
66. Yeung, M. C., D. L. Chang, R. E. Camantigue, and A. S. Lau. 1999. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells. Proc. Natl. Acad. Sci. U. S. A. 96:11860-11865.
67. Zautner, A. E., U. Korner, A. Henke, C. Badorff, and M. Schmidtke. 2003. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J. Virol. 77:10071-10077.
68. Zhong, J., et al. 2006. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80:11082-11093.